184 related articles for article (PubMed ID: 36056408)
1. Placental growth fActor Repeat sampling for Reduction of adverse perinatal Outcomes in women with suspecTed pre-eclampsia: study protocol for a randomised controlled trial (PARROT-2).
Hurrell A; Sparkes J; Duhig K; Seed PT; Myers J; Battersby C; Clark K; Green M; Hunter RM; Shennan AH; Chappell LC; Webster L
Trials; 2022 Sep; 23(1):722. PubMed ID: 36056408
[TBL] [Abstract][Full Text] [Related]
2. Repeat placental growth factor-based testing in women with suspected preterm pre-eclampsia (PARROT-2): a multicentre, parallel-group, superiority, randomised controlled trial.
Hurrell A; Webster L; Sparkes J; Battersby C; Brockbank A; Clark K; Duhig KE; Gill C; Green M; Hunter RM; Seed PT; Vowles Z; Myers J; Shennan AH; Chappell LC;
Lancet; 2024 Feb; 403(10427):619-631. PubMed ID: 38342128
[TBL] [Abstract][Full Text] [Related]
3. Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial.
Duhig KE; Myers J; Seed PT; Sparkes J; Lowe J; Hunter RM; Shennan AH; Chappell LC;
Lancet; 2019 May; 393(10183):1807-1818. PubMed ID: 30948284
[TBL] [Abstract][Full Text] [Related]
4. Repeat Placental Growth Factor-Based Testing in Women With Suspected Preterm Preeclampsia: A Stratified Analysis of the PARROT-2 Trial.
Hurrell A; Webster L; Sparkes J; Battersby C; Brockbank A; Clark K; Duhig KE; Gill C; Green M; Hunter RM; Seed PT; Vowles Z; Myers J; Shennan AH; Chappell LC;
Hypertension; 2024 Jul; 81(7):1561-1573. PubMed ID: 38708607
[TBL] [Abstract][Full Text] [Related]
5. Role of placental, fetal and maternal cardiovascular markers in predicting adverse outcome in women with suspected or confirmed pre-eclampsia.
Reddy M; Palmer K; Rolnik DL; Wallace EM; Mol BW; Da Silva Costa F
Ultrasound Obstet Gynecol; 2022 May; 59(5):596-605. PubMed ID: 34985800
[TBL] [Abstract][Full Text] [Related]
6. Placental Growth Factor (PlGF)- Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2023; 23(3):1-146. PubMed ID: 37284279
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal assessment of angiogenic markers in prediction of adverse outcome in women with confirmed pre-eclampsia.
Binder J; Palmrich P; Kalafat E; Haberl C; Schirwani N; Pateisky P; Khalil A
Ultrasound Obstet Gynecol; 2023 Dec; 62(6):843-851. PubMed ID: 37265117
[TBL] [Abstract][Full Text] [Related]
8. Multicentre randomised trial of screening with sFlt1/PlGF and planned delivery to prevent pre-eclampsia at term: protocol of the PE37 study.
Llurba E; Crispi F; Crovetto F; Youssef L; Delgado JL; Puig I; Mora J; Krofta L; Mackova K; Martinez-Varea A; Tubau A; Ruiz A; Paya A; Prat M; Chantraine F; Comas C; Kajdy A; Lopez-Tinajero MF; Figueras F; Gratacos E;
BMJ Open; 2024 Mar; 14(3):e076201. PubMed ID: 38458783
[TBL] [Abstract][Full Text] [Related]
9. Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: ruling out pre-eclampsia for up to 4 weeks and value of retesting.
Zeisler H; Llurba E; Chantraine FJ; Vatish M; Staff AC; Sennström M; Olovsson M; Brennecke SP; Stepan H; Allegranza D; Schoedl M; Grill S; Hund M; Verlohren S
Ultrasound Obstet Gynecol; 2019 Mar; 53(3):367-375. PubMed ID: 30014562
[TBL] [Abstract][Full Text] [Related]
10. PARROT Ireland: Placental growth factor in Assessment of women with suspected pre-eclampsia to reduce maternal morbidity: a Stepped Wedge Cluster Randomised Control Trial Research Study Protocol.
Hayes-Ryan D; Hemming K; Breathnach F; Cotter A; Devane D; Hunter A; McAuliffe FM; Morrison JJ; Murphy DJ; Khashan A; McElroy B; Murphy A; Dempsey E; O'Donoghue K; Kenny LC
BMJ Open; 2019 Mar; 9(2):e023562. PubMed ID: 30826791
[TBL] [Abstract][Full Text] [Related]
11. Should angiogenic markers be included in diagnostic criteria of superimposed pre-eclampsia in women with chronic hypertension?
Binder J; Kalafat E; Palmrich P; Pateisky P; Khalil A
Ultrasound Obstet Gynecol; 2022 Feb; 59(2):192-201. PubMed ID: 34165863
[TBL] [Abstract][Full Text] [Related]
12. Placental growth factor measurements in the assessment of women with suspected Preeclampsia: A stratified analysis of the PARROT trial.
Duhig KE; Myers JE; Gale C; Girling JC; Harding K; Sharp A; Simpson NAB; Tuffnell D; Seed PT; Shennan AH; Chappell LC
Pregnancy Hypertens; 2021 Mar; 23():41-47. PubMed ID: 33221705
[TBL] [Abstract][Full Text] [Related]
13. Placental growth factor in suspected preterm pre-eclampsia: a review of the evidence and practicalities of implementation.
Hurrell A; Beardmore-Gray A; Duhig K; Webster L; Chappell LC; Shennan AH
BJOG; 2020 Dec; 127(13):1590-1597. PubMed ID: 32701207
[TBL] [Abstract][Full Text] [Related]
14. Comparison of three commercially available placental growth factor-based tests in women with suspected preterm pre-eclampsia: the COMPARE study.
McCarthy FP; Gill C; Seed PT; Bramham K; Chappell LC; Shennan AH
Ultrasound Obstet Gynecol; 2019 Jan; 53(1):62-67. PubMed ID: 29575304
[TBL] [Abstract][Full Text] [Related]
15. Placental growth factor in assessment of women with suspected pre-eclampsia to reduce maternal morbidity: a stepped wedge cluster randomised control trial (PARROT Ireland).
Hayes-Ryan D; Khashan AS; Hemming K; Easter C; Devane D; Murphy DJ; Hunter A; Cotter A; McAuliffe FM; Morrison JJ; Breathnach FM; Dempsey E; Kenny LC; O'Donoghue K;
BMJ; 2021 Aug; 374():n1857. PubMed ID: 34389547
[TBL] [Abstract][Full Text] [Related]
16. Planned early delivery versus expectant management to reduce adverse pregnancy outcomes in pre-eclampsia in a low- and middle-income setting: study protocol for a randomised controlled trial (CRADLE-4 Trial).
Beardmore-Gray A; Vousden N; Charantimath U; Katageri G; Bellad M; Kapembwa K; Chinkoyo S; Vwalika B; Clark M; Hunter R; Seed P; Goudar S; Chappell LC; Shennan A
Trials; 2020 Nov; 21(1):960. PubMed ID: 33228794
[TBL] [Abstract][Full Text] [Related]
17. Use of biochemical tests of placental function for improving pregnancy outcome.
Heazell AE; Whitworth M; Duley L; Thornton JG
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD011202. PubMed ID: 26602956
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers of impaired placentation at 35-37 weeks' gestation in the prediction of adverse perinatal outcome.
Ciobanou A; Jabak S; De Castro H; Frei L; Akolekar R; Nicolaides KH
Ultrasound Obstet Gynecol; 2019 Jul; 54(1):79-86. PubMed ID: 31100188
[TBL] [Abstract][Full Text] [Related]
19. Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis.
Frampton GK; Jones J; Rose M; Payne L
Health Technol Assess; 2016 Nov; 20(87):1-160. PubMed ID: 27918253
[TBL] [Abstract][Full Text] [Related]
20. Soluble fms-like tyrosine kinase-1 and placental growth factor kinetics during and after pregnancy in women with suspected or confirmed pre-eclampsia.
Saleh L; van den Meiracker AH; Geensen R; Kaya A; Roeters van Lennep JE; Duvekot JJ; Verdonk K; Steegers EAP; Russcher H; Danser AHJ; Visser W
Ultrasound Obstet Gynecol; 2018 Jun; 51(6):751-757. PubMed ID: 28600845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
